However, it is unclear whether binding to IDH1-WT or IDH2-WT is shared by all of the glioma-derived IDH mutants, or whether IDH mutants actually bind a significant portion of IDH1-WT or IDH2-WT molecules to exert this dominant negative function in cells. This evidence concerns the gene IDH1 and central nervous system cancer.